Experiences with galactosemia in Croatia

1 Medicinski fakultet Sveučilišta u Zagrebu 2 Klinika za pedijatriju, Klinički bolnički centar Zagreb 3 Klinika za pedijatriju, Klinički bolnički centar Split 4 Medicinski fakultet Sveučilišta u Splitu 5 Sveučilišni odjel zdravstvenih studija, Sveučilište u Splitu 6 Klinika za pedijatriju, Klinički bolnički centar Osijek 7 Medicinski fakultet, Sveučilište Josipa Jurja Strossmayera u Osijeku 8 Služba za prehranu i dijetetiku, Klinički bolnički centar Zagreb 9 SE I. sz. Gyermekgyógyászati Klinika, Anyagcsere Szűrő és Diagnosztikai Központ, Budapest, Hungary 10 Metabolism & Genetics Group, Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Portugal 11 Department of Biochemistry and Human Biology, Faculty of Pharmacy, Universidade de Lisboa, Portugal 12 Klinički zavod za laboratorijsku dijagnostiku, Klinički bolnički centar Zagreb Izvorni rad | Original article

[1]  I. Rivera,et al.  Galactokinase deficiency: lessons from the GalNet registry , 2020, Genetics in Medicine.

[2]  D. An,et al.  Novel mRNA-Based Therapy Reduces Toxic Galactose Metabolites and Overcomes Galactose Sensitivity in a Mouse Model of Classic Galactosemia. , 2020, Molecular therapy : the journal of the American Society of Gene Therapy.

[3]  Merel E. Hermans,et al.  Cognitive functioning in patients with classical galactosemia: a systematic review , 2019, Orphanet Journal of Rare Diseases.

[4]  M. Kotb,et al.  Screening for galactosemia: is there a place for it? , 2019, International journal of general medicine.

[5]  S. Waisbren,et al.  The natural history of classic galactosemia: lessons from the GalNet registry , 2019, Orphanet Journal of Rare Diseases.

[6]  G. Tamiya,et al.  The prevalence of GALM mutations that cause galactosemia: A database of functionally evaluated variants. , 2019, Molecular genetics and metabolism.

[7]  M. Epstein,et al.  Developmental Outcomes in Duarte Galactosemia , 2019, Pediatrics.

[8]  O. Ohara,et al.  Biallelic GALM pathogenic variants cause a novel type of galactosemia , 2018, Genetics in Medicine.

[9]  A. Lund,et al.  Extreme neonatal hyperbilirubinemia, acute bilirubin encephalopathy, and kernicterus spectrum disorder in children with galactosemia , 2018, Pediatric Research.

[10]  Robert de Jonge,et al.  Recommendations for newborn screening for galactokinase deficiency: A systematic review and evaluation of Dutch newborn screening data. , 2018, Molecular genetics and metabolism.

[11]  T. Yuzyuk,et al.  Biochemical changes and clinical outcomes in 34 patients with classic galactosemia , 2018, Journal of Inherited Metabolic Disease.

[12]  I. Rivera,et al.  Molecular basis and clinical presentation of classic galactosemia in a Croatian population , 2017, Journal of pediatric endocrinology & metabolism : JPEM.

[13]  M. Pasquali,et al.  Laboratory diagnosis of galactosemia: a technical standard and guideline of the American College of Medical Genetics and Genomics (ACMG) , 2017, Genetics in Medicine.

[14]  S. Ferdinandusse,et al.  Galactose Epimerase Deficiency: Expanding the Phenotype. , 2017, JIMD reports.

[15]  J. H. van der Lee,et al.  International clinical guideline for the management of classical galactosemia: diagnosis, treatment, and follow-up , 2016, Journal of Inherited Metabolic Disease.

[16]  B. Jansma,et al.  Grey matter density decreases as well as increases in patients with classic galactosemia: A voxel-based morphometry study , 2016, Brain Research.

[17]  R. Villares,et al.  Appropriateness of newborn screening for classic galactosaemia: a systematic review , 2016, Journal of Inherited Metabolic Disease.

[18]  B. Bernardi,et al.  Teaching NeuroImages: Galactitol peak and fatal cerebral edema in classic galactosemia , 2016, Neurology.

[19]  P. Rudd,et al.  Effects of temporary low-dose galactose supplements in children aged 5–12 y with classical galactosemia: a pilot study , 2015, Pediatric Research.

[20]  L. Giordano,et al.  Clinical and molecular spectra in galactosemic patients from neonatal screening in northeastern Italy: structural and functional characterization of new variations in the galactose-1-phosphate uridyltransferase (GALT) gene. , 2015, Gene.

[21]  Marco Spada,et al.  Newborn screening for galactosemia: a 30-year single center experience , 2015, World Journal of Pediatrics.

[22]  I. Rivera,et al.  Functional correction by antisense therapy of a splicing mutation in the GALT gene , 2014, European Journal of Human Genetics.

[23]  R. Ramos,et al.  Functional and structural impact of the most prevalent missense mutations in classic galactosemia , 2014, Molecular genetics & genomic medicine.

[24]  Dean P. Jones,et al.  Manganese-based superoxide dismutase mimics modify both acute and long-term outcome severity in a Drosophila melanogaster model of classic galactosemia. , 2014, Antioxidants & redox signaling.

[25]  G. Berry,et al.  Classic Galactosemia and Clinical Variant Galactosemia , 2014 .

[26]  A. Facchiano,et al.  Mutation spectrum in the French cohort of galactosemic patients and structural simulation of 27 novel missense variations. , 2012, Molecular genetics and metabolism.

[27]  R. Green,et al.  The adult galactosemic phenotype , 2012, Journal of Inherited Metabolic Disease.

[28]  Jodie L. Abrahams,et al.  IgG N-glycans as potential biomarkers for determining galactose tolerance in Classical Galactosaemia. , 2012, Molecular genetics and metabolism.

[29]  J. Hennermann,et al.  Features and outcome of galactokinase deficiency in children diagnosed by newborn screening , 2011, Journal of Inherited Metabolic Disease.

[30]  J. Fridovich-Keil,et al.  Ovarian function in girls and women with GALT-deficiency galactosemia , 2010, Journal of Inherited Metabolic Disease.

[31]  N. Tõnisson,et al.  Classical galactosemia in Estonia: selective neonatal screening, incidence, and genotype/phenotype data of diagnosed patients , 2010, Journal of Inherited Metabolic Disease.

[32]  Á. Schuler,et al.  Molecular and clinical analysis of patients with classic and Duarte galactosemia in western Hungary , 2010, Wiener klinische Wochenschrift.

[33]  Y. Kaji,et al.  Hypergalactosemia in early infancy: Diagnostic strategy with an emphasis on imaging , 2009, Pediatrics international : official journal of the Japan Pediatric Society.

[34]  Lora J. H. Bean,et al.  Origins, distribution and expression of the Duarte-2 (D2) allele of galactose-1-phosphate uridylyltransferase , 2009, Human molecular genetics.

[35]  P. Gallagher,et al.  Duarte (DG) galactosemia: a pilot study of biochemical and neurodevelopmental assessment in children detected by newborn screening. , 2008, Molecular genetics and metabolism.

[36]  Rong Mao,et al.  Mutation database for the galactose‐1‐phosphate uridyltransferase (GALT) gene , 2007, Human mutation.

[37]  A. Bosch.  Classical galactosaemia revisited , 2006, Journal of Inherited Metabolic Disease.

[38]  James E. Morrow.  The University of Washington , 2004 .

[39]  T. Saheki,et al.  Differential diagnosis of neonatal mild hypergalactosaemia detected by mass screening: Clinical significance of portal vein imaging , 2004, Journal of Inherited Metabolic Disease.

[40]  R. Wanders,et al.  Clinical features of galactokinase deficiency:A review of the literature , 2003, Journal of Inherited Metabolic Disease.

[41]  C. Vermeer,et al.  Bone mineral density in patients with classic galactosaemia , 2002, Archives of disease in childhood.

[42]  J. Fridovich-Keil,et al.  Relationship between Genotype, Activity, and Galactose Sensitivity in Yeast Expressing Patient Alleles of Human Galactose-1-phosphate Uridylyltransferase* , 2001, The Journal of Biological Chemistry.

[43]  Carol J. Saunders,et al.  Functional analysis of the human galactose-1-phosphate uridyltransferase promoter in Duarte and LA variant galactosemia. , 2001, Molecular genetics and metabolism.

[44]  M. Asada,et al.  Molecular basis for phenotypic heterogeneity in galactosaemia: prediction of clinical phenotype from genotype in Japanese patients , 1999, European Journal of Human Genetics.

[45]  O. Tighe,et al.  Genetic basis of transferase-deficient galactosaemia in Ireland and the population history of the Irish Travellers , 1999, European Journal of Human Genetics.

[46]  G. Donnell,et al.  Long-term prognosis in galactosaemia: Results of a survey of 350 cases , 1990, Journal of Inherited Metabolic Disease.

[47]  M. Kogut,et al.  Hypergonadotropic hypogonadism in female patients with galactosemia. , 1981, The New England journal of medicine.

[48]  S. Waisbren,et al.  Bone Health in Classic Galactosemia: Systematic Review and Meta-Analysis. , 2017, JIMD reports.

[49]  E. Puscheck,et al.  Primary ovarian insufficiency in classic galactosemia: current understanding and future research opportunities , 2017, Journal of Assisted Reproduction and Genetics.

[50]  K. Wierenga,et al.  Innovative therapy for Classic Galactosemia - tale of two HTS. , 2012, Molecular genetics and metabolism.

[51]  M. Leonard,et al.  Official Positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Pediatric Position Development Conference. , 2008, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

[52]  J. Stockman.  Acute Liver Failure in Children: The First 348 Patients in the Pediatric Acute Liver Failure Study Group , 2008 .

[53]  M. Epstein,et al.  Epimerase-deficiency galactosemia is not a binary condition. , 2006, American journal of human genetics.

[54]  Peter Bross,et al.  The Metabolic and Molecular Basis of Inherited Disease: Protein Folding and Misfolding: the Role of Cellular Protein Quality Control Systems in Inherited Disorders , 2005 .

[55]  U. Wendel,et al.  Age dependence of endogenous galactose formation in Q188R homozygous galactosemic patients. , 2004, Molecular genetics and metabolism.

[56]  V. Schwarz.  Disorders of galactose metabolism , 1969 .